AbbVie, Inc.

AbbVie, Inc.

AbbVie, Inc.

Overview
Date Founded

2013

Headquarters

1 North Waukegan Road North Chicago IL 60064-6400

Type of Company

Public

Employees (Worldwide)

47K

Industries

Pharmaceuticals
Hospitals & Patient Services
Medical Support Services
Biotechnology

Company Description

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the discovery, development, manufacture and sale of a line of proprietary pharmaceutical products. It is focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C and human immunodeficiency virus; neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; as well as other serious health conditions. The company was founded on 2013 and is headquartered in North Chicago, IL.

Contact Data
Trying to get in touch with decision makers at AbbVie, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

Vice Chairman & President

Chief Financial Officer & Executive Vice President

Vice Chairman, External Affairs & Chief Legal Officer

Vice President, Deputy General Counsel

Chief Commercial Officer

Executive Vice President & Chief Human Resources Officer

Chief Strategy Officer

Chief Equity Officer

Vice President, Principal Accounting Officer & Controller

Board of Directors

Chief Executive Officer at AbbVie, Inc.

President at United Airlines Holdings, Inc.

Industry Advisor at Madison Dearborn Partners LLC

President & Chief Executive Officer at Austin Investment Advisors

President at Abbott Laboratories (Puerto Rico), Inc.

Former Partner at Clayton Dubilier & Rice LLC

Former Chief Financial Officer at Caterpillar, Inc.

SEE Schedule at Northwestern Memorial Healthcare Group Return

Dean at Yale University - Yale School of Medicine

Former Director & Senior Vice President at The Boston Consulting Group, Inc.

Paths to AbbVie, Inc.
Potential Connections via
Relationship Science
You
AbbVie, Inc.
Owners & Shareholders
Details Hidden

SSgA FM’s methods of analysis include quantitative, fundamental, technical, cyclical, indexing, arbitrage, charting and other strategy specific methods. They offer a broad range of strategies including: Active, Enhanced, and Passive Equity; Active & Passive Debt; Cash Management; Multi-Asset Class Solutions; Real Estate (including Direct Real Estate); Senior Loans; Managed Futures; and Private Equity. Active equity strategies include enhanced equity and active quantitative strategies. The strategies cover market-cap and style segments of the market including: large-cap core, large-cap growth, large-cap value, mid-cap, small-cap, small-cap value, all-cap, and long-short equity. They also manage long-short and long-short market neutral strategies. SSgA FM’s Active & Passive Debt strategies offers a range of investment styles from passive to active, short to long duration, tax-exempt, sovereign to high yield, and single country to global. The firm’s Cash Management strategies seek to generate current income while preserving capital and liquidity by investing in diversified portfolios of short-term securities. SSgA FM's Multi-Asset Class strategies employ an asset allocation model as means of diversification and seek to position assets among major investment categories. Their Multi Asset Class Solutions strategies employ an asset allocation model as a method of diversification that aims to position assets among major investment categories. SSgA FM’s Managed Futures strategy allocates assets using two approaches: a managed futures strategy and a fixed income strategy. The firm’s Private Equity strategies focus on rigorous partner selection, thorough evaluation of quality investment opportunities, and fundamental, research-driven research.

Details Hidden

CWGI is the investment adviser to the American Funds Group, a family of 30 funds marketed to individuals exclusively through financial advisers and other intermediaries. American Funds are also used as investment vehicles for 401ks, other retirement plans, variable annuities and 529 college savings plans. The funds have the following characteristics: (1) a long-term, value-oriented approach; (2) long-established, global research; (3) a multiple portfolio counselor system that combines teamwork with individual accountability; (4) experienced, long-tenured investment professionals; and (5) a commitment to low operating expenses, among the lowest in the fund industry. CWGI uses a Multiple Portfolio Counselor System wherein the assets of each fund are divided into smaller, more manageable portions. Research analysts typically manage a segment as well, bringing their expertise directly to bear on the fund's results and portfolio counselors are free to make their own decisions. Investment decisions are based on internal research.

Details Hidden

BHI-IM employs the value investing principles of Benjamin Graham. Their investment approach focuses on buying shares of companies as a long-term investment. The firm seeks to invest in businesses that are easy to understand and have high ROE, exceptional management teams and limited debt. Rather than a diversified stock portfolio, BHI-IM invests in a small number of trusted investments that are overweighed in order to leverage the expected returns. The firm owns stock in a diverse group of over 50 public and private companies in wide range of industries including, but not limited to, manufacturing, retail, energy and finance. Investments are typically financed using the float from Berkshire Hathaway, Inc.'s insurance operations. Securities are sold when the firm no longer feels comfortable with the fundamentals of a company.

Recent Transactions
Details Hidden

AbbVie, Inc. purchases Allergan Ltd. (Ireland)

Details Hidden

AbbVie, Inc. purchases Mavupharma, Inc. from Frazier Healthcare Partners, Alpine Bioventures GP LLC

Details Hidden

AbbVie, Inc. purchases Stemcentrx, Inc. from Sequoia Capital, Western Technology Investment, The Founders Fund Management LLC, Artis Ventures Management LP

Insider Transactions
Details Hidden
Details Hidden
Transaction Advisors
Legal Advisor

Advised onAbbVie, Inc. purchases Allergan Ltd. (Ireland)

Investment Advisor

Advised onAbbVie, Inc. purchases Allergan Ltd. (Ireland)

Legal Advisor

Advised onAbbVie, Inc. purchases Pharmacyclics LLC

Associate

Advised onAbbVie, Inc. purchases Mavupharma, Inc. from Frazier Healthcare Partners, Alpine Bioventures GP LLC

Legal Advisor

Advised onAbbVie, Inc. purchases Allergan Ltd. (Ireland)

Lender

Advised onAbbVie, Inc. purchases Pharmacyclics LLC

Advisors & Consultants
Legal Advisor

Partner at Jones Day

Legal Advisor

Co-Chair, Product Liability Litigation Practice Group at Shook, Hardy & Bacon LLP

Legal Advisor

Partner at Latham & Watkins LLP

Clients

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas, such as immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular & metabolic diseases. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular & neurovascular, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Seattle Genetics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in pivotal trial for patients with relapsed or refractory hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1998 and is headquartered in Bothell, Washington.

Biogen has some of the world’s best neurologists and neuroscientists. They engage with physicians and scientific leaders around the world with the aim to further medical research. Their focus on neuroscience, their deep scientific expertise and courage to take risks makes them leaders in the research and development of medicines to transform neuroscience to benefit society. Their technology and engineering capabilities create novel ways to seamlessly transition products from development to manufacturing with the intent of bringing their high-quality medicines to market faster. They respect the contributions of health care providers caring for people living with neurological diseases. They honor the important role of caregivers, families and friends who care about them.

Key Stats and Financials As of 2020
Market Capitalization
$187B
Total Enterprise Value
$258B
Earnings Per Share
$2.72
Revenue
$45.8B
Net Profit
$4.56B
EBITDA
$22.1B
EBITDAMargin
48.25%
Total Debt
$87.1B
Total Equity
$13.1B
Enterprise Value / Sales
5.63x
Enterprise Value EBITDAOperating
11.62x
TEVNet Income
56.6x
Debt TEV
0.34x
Three Year Compounded Annual Growth Rate Of Revenue
17.53%
Non-Profit Donations & Grants
$100 - $999
2020
$1,000 - $4,999
2019
$100 +
2019
Political Donations
$750
2014
$1,000
2014
$750
2014
Investments
Details Hidden

Exicure Operating Co. operates as a biopharmaceutical company commercializing spherical nucleic acid constructs as gene regulation and modulation agents for diseases including applications in oncology, dermatology, neurology, and for immune disorders. The SNA constructs allow the use of oligonucleotide-based therapies to treat diseases in a range of tissue types. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in 2011 and is headquartered in Skokie, IL.

Details Hidden

Avaxia Biologics, Inc. operated as a clinical-stage biotechnology company. It engaged in the development of gut-targeted antibody therapeutics for gastroenterology indications. Gut-targeted antibody therapeutics is orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal (GI) tract including the mouth, throat, and intestines. The company was founded by David Poorvin and Barbara S. Fox in 2005 and was headquartered in Lexington, MA.

Details Hidden

Enanta Pharmaceuticals, Inc. operates as a biotechnology company. It engages in the research and development of molecule drugs for the treatment of viral infections and liver diseases. The firm offers the medicine under the brands Mavyret and Viekira Pak. The company was founded by Peter O. Kliem and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Investors
Details Hidden

Chief Executive Officer at Innocrin Pharmaceuticals, Inc.

Details Hidden

Investor at BitTorrent, Inc.

Details Hidden

Co-Founder at Artis Ventures Management LP

Suppliers
Galapagos NV Biotechnology | Mechelen, Belgium

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research & Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

Neurocrine Biosciences Inc. Hospitals & Patient Services | San Diego, CA

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The firm's product includes INGREZZA. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Seagen Inc. Pharmaceuticals | Bothell, WA

Seattle Genetics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in pivotal trial for patients with relapsed or refractory hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1998 and is headquartered in Bothell, Washington.

Awards & Honors
Rank #123
2016
Fortune Magazine - Fortune 1000 Companies
Sponsored by Fortune Magazine
Rank #123
2016
Fortune Magazine - Fortune 500 Companies
Sponsored by Fortune Magazine
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by AbbVie, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of AbbVie, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and AbbVie, Inc..